The NICE reference case requirement: more pain for what, if any, gain?
Pharmacoeconomics
.
2004;22(4):271-3.
doi: 10.2165/00019053-200422040-00006.
Authors
Amiram Gafni
,
Stephen Birch
PMID:
14974877
DOI:
10.2165/00019053-200422040-00006
No abstract available
Publication types
Comment
Letter
MeSH terms
Delivery of Health Care / economics*
Delivery of Health Care / standards
Drug Industry / economics*
Drug Industry / standards
England
Quality-Adjusted Life Years
Technology Assessment, Biomedical / economics*
Wales